Advesya’s Post

Just a reminder that our CEO Ksenija Pavletic and our CSO Richard C. A. Sainson will be attending the upcoming ESMO conference starting next week on September 13th Our colleagues will be there to discuss our innovative approach to targeting IL1RAP using our cell therapy, #CCTx001, and our ADCs, #ADV101, which are currently being developed for the treatment of AML and solid tumors. If you're attending, they’d love to connect—reach out and learn more! 🌍🤝 #ESMO2024 #ADCs #SolidTumors #Oncology #Innovation #Collaboration #CellTherapy #Networking #AML #ADV101 #CCTx001

🌍🔬 Today is World Leukemia Day—a day to raise awareness and show support for everyone affected by leukemia. At Advesya, we are deeply committed to advancing the fight against leukemia. Our team is dedicated to developing innovative solutions and provide new life-saving treatments to patients across the globe. Let’s come together today to raise awareness and continue pushing forward in the mission to find a cure. 🎗️ 💛 🩸 #WorldLeukemiaDay #FightLeukemia #InnovateForLife #ResearchForACure #CCTx001 #ADV101 #AML

🔬 Really interesting to read about this new study on targeting IL-1RAP in AML! IL-1RAP is highly expressed on AML blasts and leukemic stem cells but not on healthy Hematopoietic stem cells, making it an ideal target for selective cancer therapy. This research introduces a T-cell engager that specifically targets IL-1RAP on AML cells and LSCs, showing great promise in eliminating the disease with minimal impact on healthy cells. Targeting IL-1RAP could revolutionize AML treatment, especially for patients with relapsed or refractory disease, by addressing the root of the disease and preventing recurrence. #AML #CancerResearch #Immunotherapy #HealthcareInnovation #CCTx001 #ADV101 Link: DOI:10.1186/s13045-024-01586-x

🚀 We are delighted to announce that Advesya has received approval from the EMA to start the phase 1/2 trial of our investigational lead asset, CCTx-001, to address the unmet medical needs of patients with relapse and refractory acute myeloid leukemia (AML).   The RESOLVE-AML-001 study will determine the recommended phase 2 dose of CCTx-001 and will assess safety, tolerability, and clinical activity in patients with relapsed/refractory AML. AML is a cancer of the bone marrow and the blood that progresses rapidly without treatment.Advesya is committed to accelerating the development of innovative cancer treatments for patients suffering from this hard-to-treat hematological cancer and who currently have no treatment options. Learn more 👉 www.advesya.com #ClinicalTrials #CellTherapy #Hematology #CancerResearch #AML #InnovativeTherapies #PatientCare #Healthcare #Biotech #CCTx001

🎗️ July is Sarcoma and Bone Cancer Awareness Monthn 🎗️🔬 As we raise awareness for sarcoma and bone cancer this month, let’s highlight the crucial role of Advesya's #ADV101 that targets #IL1RAP which is involved in the progression and dissemination of #EwingSarcoma Let's come together to spread awareness, support ongoing research, and advocate for advancements in novel therapies. https://lnkd.in/g_3pTbZW #SarcomaAwareness #BoneCancerAwareness #CancerResearch #ADC

🚀 Exciting developments in potential AML treatment! Sharing this video from #EHA24 where Dr. Nicolas Boissel discusses CCTx-001, a novel approach to tackle AML. CCTx-001 is a first-in-class autologous CAR-T therapy against IL-1RAP that is already showing promising preclinical results . https://lnkd.in/e-mU-zss #EHA24 #CARTCellTherapy #AML #Hematology #CancerResearch #CCTX001 #IL1RAP #Advesya